Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2018

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2018


  • Products Id :- GMDHC1664TDB
  • |
  • Pages: 110
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)-Pipeline Review, H2 2018

Summary

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report Cellular Tumor Antigen p53-Pipeline Review, H2 2018, outlays comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)-Tumor protein p53 also known as p53 is any isoform of a protein encoded by TP53 gene. TP53 gene is the most frequently mutated gene in human cancer indicating that the TP53 gene plays a crucial role in preventing cancer formation. Activated p53 binds DNA and activates expression of several genes including microRNA miR-34a, WAF1/CIP1 encoding for p21 and hundreds of other down-stream genes. p21 binds to the G1-S/CDK (CDK4/CDK6, CDK2, and CDK1) complexes (molecules important for the G1/S transition in the cell cycle) inhibiting their activity.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 3, 4 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Respiratory and Toxicology which include indications Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Ovarian Cancer, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Small-Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma Of The Gastroesophageal Junction, Alopecia, Anaplastic Astrocytoma, Bladder Cancer, Brain Cancer, Brain Tumor, Cervical Cancer, Chemotherapy Effects, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Hematological Tumor, Hepatic-Colorectal Metastasis, Kidney Transplant Rejection, Leukemias, Malignant Pleural Effusion, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Oligodendroglioma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Recurrent Medulloblastoma, Refractory Medulloblastoma, Renal Cell Carcinoma, Retinoblastoma, Soft Tissue Sarcoma and Solid Tumor.

Furthermore, this report also reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)

- The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects

- The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)-Overview

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)-Companies Involved in Therapeutics Development

Actavalon Inc

Aprea AB

CanBas Co Ltd

Cotinga Pharmaceuticals Inc

Innovation Pharmaceuticals Inc

ORCA Therapeutics BV

OSE Immunotherapeutics

Quark Pharmaceuticals Inc

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)-Drug Profiles

APR-246-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AU-14022-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBS-9106-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

contusugene ladenovec-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

COTI-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate p53 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kevetrin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LYN-00103-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MHY-449-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MJ-05-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Viruses to Activate p53 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSE-2101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

p28-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPAL-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPI-1002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate p53 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGT-53-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate p53 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Oncology and Viral Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Cellular Tumor Antigen p53 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZMC-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)-Dormant Products

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)-Discontinued Products

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)-Product Development Milestones

Featured News & Press Releases

Jul 09, 2018: Quark Pharmaceuticals Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

Jul 05, 2018: OSE Immunotherapeutics Receives a EUR435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi

Jul 02, 2018: OSE Immunotherapeutics Receives IDMC Approval to Continue Atalante 1 Phase 3 NSCLC Clinical Trial of Tedopi

Jun 17, 2018: Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm

Jun 05, 2018: Stemline Therapeutics Announces Positive Data Presentations on SL-801 at ASCO

May 24, 2018: Cotinga Pharmaceuticals Announces FDA Clearance of Significant Protocol Changes for COTI-2 Clinical Program

May 17, 2018: Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the 2018 American Society of Clinical Oncology Annual Meeting

May 17, 2018: Stemline Therapeutics Announces Presentation of SL-801 Clinical Data at the Upcoming ASCO Annual Meeting

Apr 26, 2018: Stemline Therapeutics Announces Clinical Presentation of SL-801 at the Upcoming ASCO Annual Meeting

Apr 16, 2018: Karolinska Development's portfolio company Aprea presents initial results from the ongoing phase Ib/II study with APR-246 and azacitidine for the treatment of Mutant Myelodysplastic Syndromes

Apr 03, 2018: Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Mar 26, 2018: Combination breast cancer therapy targets both tumor cells and the blood vessels that supply them, MU researchers find

Mar 20, 2018: Cotinga Pharmaceuticals Provides Update on COTI-2 Clinical Programs

Mar 15, 2018: OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

Feb 27, 2018: OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Actavalon Inc, H2 2018

Pipeline by Aprea AB, H2 2018

Pipeline by CanBas Co Ltd, H2 2018

Pipeline by Cotinga Pharmaceuticals Inc, H2 2018

Pipeline by Innovation Pharmaceuticals Inc, H2 2018

Pipeline by ORCA Therapeutics BV, H2 2018

Pipeline by OSE Immunotherapeutics, H2 2018

Pipeline by Quark Pharmaceuticals Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Dormant Products, H2 2018 (Contd..3), H2 2018

Dormant Products, H2 2018 (Contd..4), H2 2018

Dormant Products, H2 2018 (Contd..5), H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Actavalon Inc

Aprea AB

CanBas Co Ltd

Cotinga Pharmaceuticals Inc

Innovation Pharmaceuticals Inc

ORCA Therapeutics BV

OSE Immunotherapeutics

Quark Pharmaceuticals Inc

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Therapeutic Products under Development, Key Players in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Therapeutics, Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Pipeline Overview, Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Pipeline, Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Pipeline Assessment

select a license
Single User License
USD 3500 INR 249655
Site License
USD 7000 INR 499310
Corporate User License
USD 10500 INR 748965

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com